PerkinElmer Stock Continues to Climb | GenomeWeb

PerkinElmer Stock Continues to Climb

Shares in PerkinElmer rose 5.54 percent for the five-day trading period ended Tuesday, continuing a steady ascent over recent weeks. The firm's shares closed at $21.15 on Tuesday, a price not reached since March 29, when PKI's shares rose as high as $21.97. Its low for the last three months was $18, which occurred on June 27. The volume of trading in the firm's shares was also relatively heavy early this week, though no news was announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.